Eidos therapeutics, inc. (EIDX)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16
Cash Flows From Operating Activities:
Net loss

-37,835

-40,725

-11,941

-2,542

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

77

56

4

0

Stock-based compensation expense

5,373

2,526

1,148

107

Accrued interest on Convertible Promissory Notes payable

-

48

-

1

Change in fair value of derivative liability

-17

100

-

-6

Change in fair value of redeemable convertible preferred stock tranche liabilities

-

-630

75

-151

Change in fair value of redeemable convertible preferred stock warrant liability

-

-2,628

-

-

Issuance of common stock in exchange for services and technology

-

7

5

9

Amortization of debt discount

108

963

-

-

Loss on disposal of asset

-59

-

-

-

Gain on extinguishment of leasehold liability

69

-

-

-

Changes in assets and liabilities:
Related party receivable

51

-33

62

5

Prepaid expenses and other current assets

2,889

1,305

477

7

Other assets

5,708

752

174

7

Accounts payable

1,195

1,390

472

52

Accrued expenses and other liabilities

8,015

1,416

1,070

117

Related party payable

60

-116

313

59

Net cash used in operating activities

-31,648

-33,301

-9,717

-2,059

Cash Flows From Investing Activities:
Purchases of property and equipment

227

150

53

-

Net cash used in investing activities

-227

-150

-53

-

Cash Flows From Financing Activities:
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs

-

63,875

12,993

3,927

Proceeds from long-term debt, net of debt discount and issuance costs

17,500

-

-

-

Payment of deferred financing costs

348

-

-

-

Proceeds from issuance of Convertible Promissory Notes payable

-

10,000

-

-

Proceeds from issuance of common stock under employee stock plan

487

160

-

-

Proceeds from issuance of common stock upon exercise of stock options and restricted stock

1,010

96

318

-

Proceeds from the issuance of common stock in at-the-market offering

-

-

-

63

Proceeds from issuance of common stock in initial public offering, net of issuance costs

-

110,970

-

-

Net cash provided by financing activities

65,885

185,101

13,311

3,990

Net increase (decrease) in cash and cash equivalents

34,010

151,650

3,541

1,931

Other supplemental information
Interest paid

74

-

-

-

Supplemental disclosure of non-cash activities:
Settlement of redeemable convertible preferred stock tranche liability through issuance of preferred stock

-

694

240

123

Lease liability arising from the right of use asset

5,155

-

-

-

Vesting of restricted stock and early exercised options

149

170

38

-

Conversion of Convertible Promissory Notes payable and accrued interest into redeemable convertible preferred stock

-

14,354

-

32

Conversion of redeemable convertible preferred stock to common stock at closing of initial public offering

-

95,887

-

-

Reclassification of redeemable convertible preferred stock warrant liability to common stock at closing of initial public offering

-

3,506

-

-

Embedded derivative liability

1,147

-

-

-

Tenant improvements paid by landlord

959

-

-

-

Open Market Sale Agreement
Proceeds from the issuance of common stock in at-the-market offering

23,900

-

-

-

Alexion
Proceeds from the issuance of common stock

23,309

-

-

-